查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370897

Alpha-1 抗胰蛋白酶缺乏症市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、給藥途徑、配銷通路、地區、競爭細分。

Alpha-1 Antitrypsin Deficiency Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Route Of Administration, By Distribution Channel, By Region, By Competition.
出版日期: | 出版商: TechSci Research | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球 Alpha-1 抗胰蛋白酶缺乏症市場估值達到 18,0936 萬美元，在整個預測期內有望實現令人印象深刻的成長，預計到 2028 年年複合成長率 (CAGR) 為 6.49%，預計到2028 年將達到26.2718 億美元。Alpha-1 抗胰蛋白酶缺乏症（Alpha-1 抗胰蛋白酶缺乏症）是一種影響肺部和肝臟的罕見遺傳性疾病。它是由於 α-1 抗胰蛋白酶蛋白水平不足而引起的，導致更容易患肺病和肝病。儘管 Alpha-1 抗胰蛋白酶缺乏症很罕見，但它會嚴重影響患者的生活品質和醫療保健系統。隨著研究的進步和意識的傳播，Alpha-1 抗胰蛋白酶缺乏症市場正在發生變化，挑戰與機會並存。

Alpha-1 抗胰蛋白酶是一種肝臟產生的蛋白質，對於保護肺部免受酵素引起的發炎損傷至關重要。在 Alpha-1 抗胰蛋白酶缺乏症的情況下，基因突變會導致錯誤折疊的蛋白質在肝臟中積累，而不是釋放到血液中。這種缺陷會增加對慢性阻塞性肺病（COPD）等肺部疾病和肝硬化等肝臟疾病的易感性。

市場概況
預測期 2024-2028
2022 年市場規模 180936萬美元
2028 年市場規模 262718萬美元
2023-2028 年年複合成長率 6.49%
成長最快的細分市場 Alpha-1 蛋白酶抑制劑
最大的市場 北美洲

政府措施和研究經費推動了全球 Alpha-1 抗胰蛋白酶缺乏症市場。隨著對 Alpha-1 抗胰蛋白酶缺乏症等罕見疾病的認知不斷提高，支持研究、診斷和治療開發的政策和計劃也越來越受到關注。研究計畫、臨床試驗和患者支持的資金吸引了製藥公司和研究人員，加速了進步。

主要市場促進因素

  • 1.增加患者基礎：由於患者人數的增加，全球 Alpha-1 抗胰蛋白酶缺乏症市場大幅成長。雖然是一種罕見的遺傳性疾病，但隨著意識和診斷精確度的提高，病例報告不足和誤診導致了更大的目標群體。病例增加促使製藥和研究重點增加，推動市場擴張。
  • 2.監管支持：研究人員、臨床醫生、患者、倡導團體和製藥公司之間的合作努力促進了 Alpha-1 抗胰蛋白酶缺乏症的理解、治療和患者護理方面的進步。跨機構聯盟、藥學學術合作和數位資料共享改變了傳統的研究和治療方法，促進了進步。

主要市場挑戰

  • 1.診斷不足與誤診：Alpha-1抗胰蛋白酶缺乏症市場的一個重大挑戰在於其診斷不足和誤診。許多患者仍未被診斷或誤診為其他肺部疾病，延誤了準確的治療策略。
  • 2.認知有限：Alpha-1抗胰蛋白酶缺乏症的罕見性導致公眾和醫療保健專業人員的認知有限，導致診斷延遲和支持不足。
  • 3.複雜的治療：由於 Alpha-1 抗胰蛋白酶缺乏症的遺傳性質和雙肺肝併發症，開發有效的治療方法非常複雜，因此需要同時解決這兩個方面的治療方法。

主要市場趨勢

  • 1.技術進步：基因篩檢的技術突破能夠實現早期 Alpha-1 抗胰蛋白酶缺乏症檢測，從而實現主動干涉。精準醫學根據基因組成客製化治療方案，提高療效。基因療法和編輯探索治療遺傳根源，有可能改變疾病管理。
  • 2.協作努力：跨學科合作加速了對 Alpha-1 抗胰蛋白酶缺乏症的理解和管理。研究聯盟、製藥學術夥伴關係和患者倡導團體加速研究、創新和治療開發。

細分市場洞察

  • 1.產品：2022年，Alpha-1蛋白酶抑制劑領域引領Alpha-1抗胰蛋白酶缺乏症市場，預計將繼續其成長軌跡。透過酵素替代療法 (ERT) 補充 A1PI 水平不足有助於緩解症狀，減緩肺損傷進展。
  • 2.配銷通路：2022年，在Alpha-1抗胰蛋白酶缺乏症患者所需的綜合護理的推動下，醫院藥屋主導了市場，涉及各個學科的專家。

區域洞察

北美：該研究中心擁有領先的機構、研究中心和製藥公司，推動 Alpha-1 抗胰蛋白酶缺乏症的了解、診斷和治療。臨床試驗主要在這裡進行，可以儘早獲得新療法並鞏固北美的市場領導地位。該地區的可支配收入、醫療保健支出和覆蓋範圍鞏固了市場主導地位。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球 Alpha-1 抗胰蛋白酶缺乏症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 副產物（Alpha-1 蛋白酶抑制劑、支氣管擴張劑、皮質類固醇、氧氣治療）
    • 依給藥途徑（注射、口服、吸入）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（前 5 名市場參與者的股份）
  • 市場地圖
    • 按產品分類
    • 依給藥途徑
    • 按配銷通路
    • 按地區

第 6 章：北美 Alpha-1 抗胰蛋白酶缺乏症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區

第 7 章：歐洲 Alpha-1 抗胰蛋白酶缺乏症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區

第 8 章：亞太地區 Alpha-1 抗胰蛋白酶缺乏症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區

第 9 章：南美洲 Alpha-1 抗胰蛋白酶缺乏症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區

第 10 章：中東與非洲 Alpha-1 抗胰蛋白酶缺乏症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第13章：競爭格局

  • 夏爾公司
  • 葛蘭素史克公司
  • CSL貝林
  • 阿斯特捷利康公司
  • 格里福斯公司
  • 梯瓦製藥工業公司
  • 勃林格殷格翰國際股份有限公司
  • 鐮田製藥
  • 輝瑞公司
  • 百特國際公司

第 14 章：策略建議

第 15 章：關於我們與免責聲明

簡介目錄
Product Code: 15894

The Global Alpha-1 Antitrypsin Deficiency Disease Market reached a valuation of USD 1809.36 Million in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.49% up to 2028 and expected to reach USD 2627.18 Million by 2028. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is an uncommon genetic disorder impacting the lungs and liver. It arises due to insufficient levels of the alpha-1 antitrypsin protein, resulting in an elevated vulnerability to lung and liver diseases. Despite its rarity, Alpha-1 Antitrypsin Deficiency Disease significantly affects patients' quality of life and healthcare systems. As research advances and awareness spreads, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing changes, presenting both challenges and opportunities.

Alpha-1 antitrypsin is a liver-produced protein pivotal in safeguarding lungs against inflammation-induced damage from enzymes. In cases of Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to misfolded protein accumulation in the liver instead of release into the bloodstream. This deficiency heightens susceptibility to lung ailments like chronic obstructive pulmonary disease (COPD) and liver conditions such as cirrhosis.

While the Alpha-1 Antitrypsin Deficiency Disease market is relatively compact due to the disease's rarity, it garners attention from researchers, pharmaceutical firms, and healthcare providers. Notable players in diagnostics, treatments, and therapies concentrate on addressing the underlying deficiency and managing linked complications. Biotechnology, genomics, and personalized medicine progress yield targeted, effective treatments for Alpha-1 Antitrypsin Deficiency Disease, potentially revolutionizing patient outcomes.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1809.36 Million
Market Size 2028USD 2627.18 Million
CAGR 2023-20286.49%
Fastest Growing SegmentAlpha-1 Proteinase Inhibitor
Largest MarketNorth America

Government initiatives and research funding propel the global Alpha-1 Antitrypsin Deficiency Disease market. As rare disease awareness, like Alpha-1 Antitrypsin Deficiency Disease, heightens, policies and programs supporting research, diagnosis, and treatment development gain traction. Funds for research projects, clinical trials, and patient support captivate pharmaceutical companies and researchers, spurring accelerated advancements.

Primary Market Drivers

  • 1. Increasing Patient Base: The Global Alpha-1 Antitrypsin Deficiency Disease Market witnesses substantial growth due to a rising patient population. Though a rare genetic disorder, underreported cases and misdiagnoses result in a larger target group as awareness and diagnostic precision improve. Heightened cases prompt increased pharmaceutical and research focus, driving market expansion.
  • 2. Regulatory Backing: Collaborative efforts among researchers, clinicians, patients, advocacy groups, and pharmaceutical firms catalyze advancements in Alpha-1 Antitrypsin Deficiency Disease understanding, treatment, and patient care. Cross-institutional consortia, pharmaceutical-academic collaborations, and digital data sharing transform traditional research and treatment approaches, fostering progress.

Key Market Challenges

  • 1. Underdiagnosis and Misdiagnosis: A substantial challenge in the Alpha-1 Antitrypsin Deficiency Disease market lies in its underdiagnosis and misdiagnosis. Many patients remain undiagnosed or misdiagnosed as other lung conditions, delaying accurate treatment strategies.
  • 2. Limited Awareness: The rarity of Alpha-1 Antitrypsin Deficiency Disease results in limited awareness among the public and healthcare professionals, causing delayed diagnosis and insufficient support.
  • 3. Complex Treatment: Developing effective treatments for Alpha-1 Antitrypsin Deficiency Disease is intricate due to its genetic nature and dual lung-liver complications, necessitating therapies addressing both aspects.

Key Market Trends

  • 1. Technological Advancements: Technological breakthroughs in genetic screening enable early Alpha-1 Antitrypsin Deficiency Disease detection, allowing proactive intervention. Precision medicine tailors treatment based on genetic makeup, enhancing efficacy. Gene therapies and editing explore treating the genetic root, potentially transforming disease management.
  • 2. Collaborative Efforts: Cross-disciplinary collaborations accelerate Alpha-1 Antitrypsin Deficiency Disease understanding and management. Research consortia, pharmaceutical-academic partnerships, and patient advocacy groups expedite research, innovation, and treatment development.

Segment Insights

  • 1. Product: In 2022, the Alpha-1 Proteinase Inhibitor segment led the Alpha-1 Antitrypsin Deficiency Disease market and is expected to continue its growth trajectory. Replenishing deficient A1PI levels through enzyme replacement therapy (ERT) helps alleviate symptoms, slowing lung damage progression.
  • 2. Distribution Channel: In 2022, Hospital pharmacies dominated the market, driven by the comprehensive care Alpha-1 Antitrypsin Deficiency Disease patients require, involving specialists from various disciplines.

Regional Insights

North America: This research hub boasts leading institutions, research centers, and pharmaceutical companies, propelling Alpha-1 Antitrypsin Deficiency Disease understanding, diagnostics, and treatments. Clinical trials predominantly occur here, giving early access to new therapies and consolidating North America's market leadership. The region's disposable income, healthcare spending, and coverage bolster market dominance.

Key Market Players

  • Shire plc
  • GlaxoSmithKline plc
  • CSL Behring
  • AstraZeneca Plc.
  • Grifols S.A.
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim International GmbH
  • Kamada Pharmaceuticals
  • Pfizer Inc.
  • Baxter International Inc.

Report Scope:

  • In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

  • Alpha-1 Proteinase Inhibitor
  • Bronchodilato
  • Corticosteroid
  • Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

  • Injection
  • Oral
  • Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

  • Hospitals Pharmacy
  • Retail Pharmacies
  • Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

  • Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
    • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
    • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Route of Administration
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Product
        • 6.2.4.1.2.2. By Route of Administration
        • 6.2.4.1.2.3. By Distribution Channel (
      • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Product
        • 6.2.4.2.2.2. By Route of Administration
        • 6.2.4.2.2.3. By Distribution Channel
      • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Test
        • 6.2.4.3.2.2. By Route of Administration
        • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Route of Administration
        • 7.2.4.1.2.3. By Distribution Channel
      • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Route of Administration
        • 7.2.4.2.2.3. By Distribution Channel
      • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Route of Administration
        • 7.2.4.3.2.3. By Distribution Channel
      • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Route of Administration
        • 7.2.4.4.2.3. By Distribution Channel
      • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Route of Administration
        • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Product
        • 8.2.4.1.2.2. By Route of Administration
        • 8.2.4.1.2.3. By Distribution Channel
      • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Product
        • 8.2.4.2.2.2. By Route of Administration
        • 8.2.4.2.2.3. By Distribution Channel
      • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Product
        • 8.2.4.3.2.2. By Route of Administration
        • 8.2.4.3.2.3. By Distribution Channel
      • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Product
        • 8.2.4.4.2.2. By Route of Administration
        • 8.2.4.4.2.3. By Distribution Channel
      • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Product
        • 8.2.4.5.2.2. By Route of Administration
        • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Route of Administration
        • 9.2.4.1.2.3. By Distribution Channel
      • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Route of Administration
        • 9.2.4.2.2.3. By Distribution Channel
      • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Route of Administration
        • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Product
        • 10.2.4.1.2.2. By Route of Administration
        • 10.2.4.1.2.3. By Distribution Channel
      • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Product
        • 10.2.4.2.2.2. By Route of Administration
        • 10.2.4.2.2.3. By Distribution Channel
      • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Product
        • 10.2.4.3.2.2. By Route of Administration
        • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Shire plc
  • 13.2. GlaxoSmithKline plc
  • 13.3. CSL Behring
  • 13.4. AstraZeneca Plc.
  • 13.5. Grifols S.A.
  • 13.6. Teva Pharmaceutical Industries
  • 13.7. Boehringer Ingelheim International GmbH
  • 13.8. Kamada Pharmaceuticals
  • 13.9. Pfizer Inc.
  • 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer